HC Wainwright restated their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research note released on Wednesday, Benzinga reports. The firm currently has a $14.00 price target on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.48) EPS and Q4 2025 earnings at ($0.40) EPS.
PolyPid Price Performance
PolyPid stock opened at $4.94 on Wednesday. PolyPid has a one year low of $3.57 and a one year high of $13.23. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.17. The business has a fifty day moving average price of $4.95 and a 200-day moving average price of $5.02.
PolyPid (NASDAQ:PYPD – Get Free Report) last posted its earnings results on Wednesday, February 14th. The company reported ($3.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.17) by ($1.80). As a group, equities analysts anticipate that PolyPid will post -3.72 EPS for the current year.
Institutional Inflows and Outflows
PolyPid Company Profile
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Read More
- Five stocks we like better than PolyPid
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Profitably Trade Stocks at 52-Week Highs
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.